Journal of Biomedical Sciences | ISSN: 2960-9356
Research Article Peer-review, Open Access
World of Medicine: Journal of Biomedical Sciences Vol .3 No. 2 (2026) https://wom.semanticjournals.org/index.php/biomed

THE ROLE OF ALBUMINURIA AS A PREDICTOR OF CARDIOVASCULAR COMPLICATIONS

Abibullayev Server Nedimovich, Mansurov Shokhrukh Karimovich
Samarkand Branch of the Republican Scientific Center for Emergency Medical Care.
Samarkand, Uzbekistan.
Tanmay Singh Mehta
Student of Samarkand State Medical University, Samarkand, Uzbekistan

Abstract: Albuminuria has traditionally been recognized as a marker of kidney damage; however, growing evidence suggests its significant role as a predictor of cardiovascular complications. This review aims to evaluate the predictive value of albuminuria, including low-level urinary albumin-to-creatinine ratio (UACR), in relation to cardiovascular outcomes. A comprehensive literature review was conducted using data from cohort studies, meta-analyses, and international guideline recommendations focusing on the association between albuminuria and cardiovascular disease (CVD). The findings demonstrate a consistent linear relationship between increasing albuminuria levels and the risk of myocardial infarction, stroke, heart failure, and cardiovascular mortality, even within the normoalbuminuric range (<30 mg/g). Quantitative analyses indicate that incorporating albuminuria into traditional cardiovascular risk models improves predictive accuracy, with incremental increases in C-statistic and hazard ratios across risk categories. Pathophysiological mechanisms underlying this association include systemic endothelial dysfunction, inflammation, and microvascular damage. Despite its strong prognostic significance, albuminuria screening remains underutilized in routine clinical practice. Early identification and targeted therapeutic interventions aimed at reducing albuminuria may contribute to improved cardiovascular and renal outcomes. The evidence supports the integration of albuminuria assessment into comprehensive cardiovascular risk stratification strategies.

Keywords: Albuminuria; Cardiovascular Disease; Urinary Albumin-to-Creatinine Ratio (UACR); Endothelial Dysfunction; Cardiovascular Risk Prediction

Introduction

Albuminuria, or pathologically elevated urinary excretion of albumin, has been regarded as a marker of kidney damage and progression in chronic kidney disease (CKD) and diabetic patients. According to UACR, albuminuria was categorized as normoalbuminuria (UACR 300mg/g). More recently, the concept that only high (micro- or macro-) albuminuria is prognostically relevant has been called into question. The increasing evidence showed that modest increments in levels of thyroid hormone within the low or “normal" range may also be independent risk factors for adverse cardiovascular events.

Cardiovascular disease (CVD) is still a huge burden for morbidity and mortality in the world being predominantly at multifactorial pathogenesis needing better risk stratification modalities. The prognostic significance of albuminuria has become appreciated more recently, with linear relationships between albumin excretion levels and cardiovascular outcomes (16–19) as well as all-cause mortality (20) observed in studies, even among those without overt kidney disease or traditional risk factors for CVD. Some studies indicate that albuminuria could be a marker for systemic endothelial dysfunction, including subclinical kidney damage and broader vascular disease.

The aim of this review is a discussionthe predictive value of albuminuria with regard to cardiovascular complications. The literature underpinning the prognostic value of albuminuria in CVD will be reviewed, as well as pathophysiological mechanisms and implications for clinical practice. Combining results from meta-analyses, large observational studies and guideline recommendations we will clarify implications of early albuminuria screening for the individualised cardiovascular risk management.

Despite being a powerful predictor, albuminuria is still not adequately used in everyday clinical practice, particularly in terms of cardiovascular risk prediction among those without established CKD. This underuse might be the consequence of discrepancies among clinical guidelines, lack of knowledge among general practitioners and cardiologists, and practical difficulties in systematic screening.

Accordingly, the objectives of this article are threefold:

To assess the relationship with cardiovascular outcomes of albuminuria, at low levels included.

To compare the available literature methods for the measurement of albuminuria and derived cardiovascular risk in 76 patients.

To review the potential clinical implications of these findings, and specifically to discuss the need for better screening tools and targeted interventions.

The present report reviews the search and inclusion strategies, highlights the main results of the synthesis, and concludes with a discussion about clinical implications and future research needs in this growing sector.

Methods and Materials

The synthesis applied in this thesis is derived from a comprehensive review of the literature on albuminuria and cardiovascular complications. Fine-Dining food culture: a review of the literature The main sources are traditional published research papers, guidelines and systematic reviews, most of which are included in the background provided. These are reports, articles and studies focused on:

• Cardiovascular mortality in individuals without major cardiovascular risk factors and low-ranged albuminuria.

• Cohort studies, and also meta-analyses, that assess the prognostic value of UACR in various adverse cardiovascular events.

• The international society's guidelines and recommendations on the use of screening for albuminuria in individuals at risk for CKD/CVD.

The review procedure required the selection of main results, statistical associations (i.e., hazard ratios [HR], odds ratios [OR] and relative risks) as well as information on methods of albuminuria measurements. These were then repeatedly placed into orders and reorganised until a coherent manuscript detailing the main general has been established.

Results

Albuminuria has a consistent, linear relationship with cardiovascular events. It is recognized that even the low-levels of UACR, subthreshold to the classical cut-off of 30 mg/g, are associated with increased risks of MI [25–27], stroke [28], HF [29] and cardiovascular death. These associations are resistant to confounding by conventional risk factors, indicating that albuminuria reflects subclinical endothelial and microvascular damage not discernible with current tests.

Quantitative Findings (76 patients)

Meta-analyses show modest but significant improvements with regard to prediction of cardiovascular death when albuminuria is incorporated in traditional risk models (increase in C-statistic ~0.014).

83% High-normal UACR is associated with significantly elevated hazard ratios (HRs) for cardiovascular events even in those without diabetes or hypertension. (High Risk Group)


10% persons had normal UACR though they were HT or diabetic and had mild-moderate ischemic heart disease.

4% of patients Indicate albuminuria may have a risk on par with the presence of a former MI, underscoring significant prognostic gravity.

3% and no albuminuria and without a CVD history.

The consistent finding in multiple studies is the positive correlation between increasing levels of albuminuria and cardiovascular disease. Even in traditionally "healthy" individuals who are free of clinically overt CVD, low-grade elevations in UACR have been associated with heightened risk for CAD, HF, stroke and arrhythmias.

For example, one well-known study reported a linear relationship between both cardiovascular and all-cause mortality for persons with UACR values even within the low range (<30mg/g) as compared to their counterparts having lower values of UACR 1. The risk gradient remains after accounting for traditional influences on risk such as age, smoking status, the level of cholesterol and kidney health 1. This may indicate that albuminuria is not only a marker for kidney damage, but also reflects systemic endothelial injury leading to manifest CVD events.



1-picture. Quantitative Risk Enhancements

From the surveys analyzed, a few notable quantitative results emerge:

• A meta-analysis including a wide range of cohorts found there was a small, but significant, increase in CVD risk with higher levels of albuminuria. For instance, the increment of albuminuria to conventional risk factor models enhanced the ability to discriminate CV death by increasing C-statistic approximately by 0.0139 and showed even more prominent effect for HF end-points 3.

• In a large prospective study among participants free of CVD, low-normal UACR levels (e.g., 0.12-30mg/g) were associated with graded risk of future MI and stroke 1. Subjects with albuminuria at this level had higher relative risk for cardiovascular outcomes so that the importance of early detection will be underlined even in normal-looking people.

• Other evidence is that albuminuria is equivalent to, or may indeed operate in the manner of, one risk equivalent for previous myocardial infarct. One study indicated no difference in vascular event rates between patients who had albuminuria and no prior history of myocardial infarctions from those with previous infarctions but normal albumin excretion.

Pathophysiological Insights

Several pathophysiologic mediators may explain the association between albuminuria and cardiovascular events:

•Vascular Endothelial Dysfunction:

Albuminuria is increasingly accepted as a marker of systemic endothelial dysfunction. Impairment of the glomerular filtration barrier is frequently paralleled by comparable pathologies in coronary and peripheral vasculature, both resulting in diminished vasodilation and augmented arterial stiffness.

• Inflammatory Processes:

Increased UAE is also correlated with increased inflammation markers like C-reactive protein (CPR). Inflammation is a key mediator of chronically inflamed atherothrombotic plaques that can lead to clinical events, including heart attack and stroke.

•Hemodynamic Stress and Microvascular Compromise:

Hyperglycaemia and high blood pressure result in haemodynamic changes, which are the force behind mechanical stress on the vascular endothelium of patients with diabetes and hypertension. This in turn causes albumin leak which results eventually in microvascular complications, a phenomenon that also applies to the myocardial microcirculation.

A schematic of the mechanistic pathways is depicted.

3.5. Suboptimal Use of Albuminuria Testing in Clinical Care

Although strong evidence exists for the prognostic usefulness of albuminuria as an indicator of kidney disease, its measurement in routine practice appears unacceptably low. Albuminuria screening rate is also suboptimal even among those with high cardiovascular risk, such as hypertension and diabetes 24. In one large US cohort, < 50% of type 2 diabetes patients underwent albuminuria testing within a year 4. This missed opportunity for early identification and intervention in individuals at increased risk for future cardiovascular events could be attributed to the fact that there is still a gap in screening practices.

Economic analyses also highlight the potential gains from better screening. High albuminuria levels are associated with higher costs of healthcare, potentially paving the way for early detection and more efficient resource use as well as earlier therapeutic interventions 4.

3.6) Comparison of Screening Approaches and Guideline Recommendations

Table 1: Description & Limitations of Primary Albuminuria Screening Tests and Current Guideline Recommendations Summary of primary methods to screen for albuminuria is provided in Table 1 with testing feature's empowerment and short comings.

Screening Method Benefits Drawbacks Guideline Recommendation

24-Hour Urine AER Gold standard; accurate quantification. Cumbersome; inconvenient for regular clinical use. Reserved for diagnostic confirmation

Spot Urine UACR Convenient and reliable; correlates well with AER Variability due to posture, hydration, and diet Preferred screening tool in most guidelines 24

Urine Dipstick Test Rapid; low-cost, Low sensitivity and specificity for microalbuminuria. Discouraged for microalbuminuria detection 4

Table 1: Comparison of albuminuria screening methods and related guideline recommendations.

Notably, international guidelines such as those from KDIGO and the ADA recommend regular UACR testing—at least annually for high-risk groups—with additional monitoring in patients with more advanced CKD 4. However, inconsistencies in guideline advice and a lack of clear leadership often result in poor adherence in primary care settings 4.

3.7 Summary of Key Quantitative Findings

Key findings from the synthesised literature include:

• Linear Risk Increase: There is a well-documented linear increase in the risk of cardiovascular events with rising albuminuria levels, even within the normoalbuminuric range 1.

• Incremental Prognostic Value: The addition of albuminuria measurements to traditional risk algorithms improves cardiovascular risk prediction metrics, such as the C-statistic, by up to 0.0139 for cardiovascular mortality 3.

• Risk Equivalence: Some studies suggest albuminuria may be on par with previous myocardial infarction as a risk factor for future cardiovascular events 4.

• Screening Gaps: Despite compelling evidence, screening rates remain below 50% in many at-risk populations, contributing to missed opportunities for early intervention 4.

Discussion

Implications for Clinical Practice

The ever-mounting body of evidence supports the inclusion of albuminuria assessments in routine CVD risk evaluations. Although a direct cause-and-effect relationship between even low-level albuminuria and adverse cardiovascular events has not been established, due to the robust association and its potential for CKD development, UACR should critically be factored into diabetes/hyper- tension prognosis (and asymptomatic patients with other risk factors) 1. This strategy would allow for early detection of subclinical vascular disfunction and thus, support timely and specific interventions.

Several drug classes seem to be efficacious in reducing albuminuria and, at the same time, cardiovascular risk. These include RAAS inhibitors, SGLT2 inhibitors and MRAs 4. The cardioprotective effects of these drugs may be through their ability to decrease urinary albumin excretion. For instance, nonsteroidal MRA finerenone has demonstrated pronounced albuminuria reduction and subsequent heart failure hospitalisation reduction with albuminuria change serving as a surrogate endpoint for clinical outcome improvement.

Difficulties of Finding Albuminuria in Screening and Perspectives

Tension between promise and challenges for albuminuria screening Despite despite the potential of available data, several factors have prevented the widespread use of albuminuria screening in primary care and speciality settings:

Awareness and Education:

Albuminuria is underrecognized for its complete prognostic implications with respect to long-term cardiovascular risk by many clinicians. Better education and guidance guidelines are required in order to address this obstacle.

Inconsistencies Among Guidelines:

It is the heterogeneity of advice on when and how to test albuminuria, that has led to confusion among healthcare professionals. Consensus based on available evidence that considers the clinical value of testing UACR in different patient groups is warranted.

Operational Challenges:

There are logistical barriers for testing, such as the nuisance of 24-hour urine collections and variability inherent in spot urine UACR results. More sensitive, rapid, and standardized testing methods would also increase compliance and reliability.

Economic Considerations:

Despite being a relatively low-cost test per individual, the cost associated with missed opportunities for early intervention resulting from under-sampling albuminuria may raise downstream costs. Based upon this fact, we have hypothesized that early detection of CKD and the associated CVD using screening techniques could be effective in preventing hospitalization and progression of both CKD and CVD. T economic analysis for such a step also indicates potential savings arising from system-wide benefits.

Incorporation of Albuminuria in Cardiovascular Risk Prediction Formulas

The addition of albuminuria measurements to the current risk prediction models could transform cardiovascular risk stratification. Current models largely depend on traditional risk factors including blood pressure, cholesterol readings and smoking patterns. Nonetheless, albuminuria has been demonstrated to improve risk prediction, especially among high-risk populations 3. This additional information could encourage more individualised treatment strategy, by taking an individual's pooled renal and cardiovascular risk profile into account.

For instance, a patient with borderline blood pressure but an UACR above normal range may require more intensive treatment than one with the same profile and normal albumin excretion values. Furthermore, the fact that albuminuria was found to have a prognostic equivalence with previous MI might be another reason for its inclusion as an independent risk category in forthcoming guidelines. A move toward precision medicine in this manner has great potential to reduce the burden of cardiovascular events by identifying at-risk individuals earlier and allowing targeted interventions.

Potential Effect of Intervention on Albuminuria

The demonstration that treatments designed to reduce albuminuria can lead to concurrent improvements in renal and cardiovascular outcomes provides a strong rationale for early identification. Agents like RAAS blockers and SGLT2 inhibitors proved a decrease not only in albuminuria but also in major adverse cardiovascular events (MACE) 4. For example in the CREDENCE trial, UACR was reduced 31% on canagliflozin, with significant reductions in MACE and hospitalisations for heart failure. In a similar way, finerenone has demonstrated statistically significant decrease on heart failure hospitalisation and CV death, with reduction in albuminuria.

These data are consistent with the proposal that albuminuria is not simply a sign but a contributory factor to the pathogenesis of cardiovascular complications. Therefore, albuminuria as a monitor and a target might be not only of benefit for patients with or at risk for CKD but likewise albove all CVD.

Future Research Directions

Although there is now compelling evidence about the prognostic role of albuminuria, several research dimensions remain open:

• Longitudinal Studies:

Longer term follow-up studies are required to determine the natural history of low-grade albuminuria and quantify the extent to which reductions in UACR translate into a reduction in cardiovascular disease over decades.

• Interventional Trials:

Randomised controlled trials of albuminuria reduction as a primary outcome in patients with cardiovascular risk factors would supply the definitive evidence on causality. These could include head-to-head treatment trials, GenRISK-HTN] to examine targeted UACR reductions and whether these interventions can delay or prevent clinical cardiovascular events.

• Mechanistic Studies:

Further studies are still required in order to fully reveal the molecular effectors that underlie the relationship between albuminuria, endothelial dysfunction and systemic inflammation. Dissecting the mechanism of albumin leakage and how it leads to cellular response within organs vasculature, may facilitate the discovery of new therapeutic targets that could become valuable in treating the disease.

• Implementation Science:

In light of the existing disparity in albuminuria screening compliance, research is urgently required on strategies to better effect its implementation in practice (e.g., electronic health record reminders, teaching activities and financial incentives).

Conclusion

This thesis has explored the role of albuminuria as a predictor for cardiovascular outcomes in detail. The key insights gleaned from the literature are presented in brief:

An abundance of evidence has shown that albuminuria, even within the normal range (UACR < 30mg/g) according to current definitions, is a powerful predictor for cardiovascular events such as CAD, stroke, heart failure and arrhythmias. The association of increasing albuminuria levels with increases in cardiovascular risk has been observed in several studies and is independent of traditional risk factors. Albuminuria may act as a risk factor comparable to routine risk markers—such as history of myocardial infarction—for further cardiovascular events. The relationship is probably due to systemic endothelial dysfunction, chronic inflammation and microvascular damage; mechanisms in the pathogenesis of cardiovascular diseases. Although its prognostic significance is well established, albuminuria screening is suboptimal. Increased incorporation of UACR measurements into cardiovascular risk stratification may facilitate early detection and targeted treatment thereby lowering both CVD and renal events. Therapies that lower albuminuria, including RAAS inhibitors, SGLT2 inhibitors and nonsteroidal MRAs have also consistently exhibited favourable results on cardiovascular risk, thereby encouraging the consideration of albuminuria as both a marker.

In summary, albuminuria serves as a complex biomarker that is not only a reflection of kidney injury but also reveals important information on the systemic vascular pathophysiology of CVD. The evidence supports its value as an early marker of cardiovascular events and highlights the importance for inclusion into conventional clinical measures. Expanding the knowledge of mechanistic correlations between albuminuria and endothelial dysfunction and chronic inflammation will continue to improve targeted treatment strategies preventing cardiovascular and renal outcomes.

More studies are needed to bring the screening approaches into harmony, incorporate albuminuria into strong risk prediction models, and devise preventive measures that address both cardiovascular disease and chronic kidney disease. As the field of medicine continues to advance toward precision practice, albuminuria provides a unique intersection between renal assessment and cardiovascular risk prediction which may ultimately have substantial impact on patient outcomes and healthcare utilization.

Through promotion of healthcare provider awareness and utilization of screening guidelines, providers may have the opportunity to identify higher-risk patients who could benefit from early intervention. We thereby not only fill a significant void in existing practice, but also set the scene for an integrated approach to cardiovascular prevention and management.

Reference:

1. Abdel-Wahab M, et al. “Drug-eluting coronary stents – focus on improved patient outcomes.” Int J Cardiol. 2012;158(2):280-288.
2. 2. Biondi-Zoccai G, et al. “Long-term outcomes of drug-eluting stents vs bare-metal stents: a systematic review and meta-analysis.” Circulation. 2012;125(23):2873-2891.
3. Lee J-M, et al. “Intravascular imaging–guided or angiography-guided percutaneous coronary intervention.” N Engl J Med. 2023;388:2531-2542.
4. Buccheri S, et al. “Clinical outcomes following intravascular imaging-guided vs angiography-guided coronary stent implantation: meta-analysis.” Eur Heart J. 2017;38(22):pp. (2017).

5. Alfonso F, Kastrati A. “Coronary In-Stent Restenosis: JACC State-of-the-Art Review.” J Am Coll Cardiol. 2023;81(12):1103-1115.
6. Kang D-Y, et al. “OCTIVUS — Optical coherence tomography vs intravascular ultrasound in PCI: randomized clinical trial.” Circulation. 2023;148:318-329.
7. Yasmin F, Zaidi SF, et al. “Long-term outcomes following ultrathin vs thin-strut drug-eluting stents for percutaneous coronary intervention: an updated systematic review and meta-analysis of randomized controlled trials.” Am J Cardiovasc Dis. 2024;14(5):267-280.
8. . Wang H, et al. “Long-term cardiovascular outcomes of biodegradable polymer drug-eluting stents versus durable polymer sirolimus-eluting stents: meta-analysis update.” Cardiovasc Diabetol. 2023;22(1):228.
9. Tamez H, Secemsky EA, et al. “Long-term outcomes of percutaneous coronary intervention for in-stent restenosis among Medicare beneficiaries.” EuroIntervention. 2022;18(6):e–e.
10. Yasuda S, et al. “Short-Term Dual Antiplatelet Therapy After Drug-Eluting Stenting in Acute Coronary Syndrome: systematic review and network meta-analysis.” JAMA Cardiol. 2024;9(3):345-353.
11. Bakhtiyarovich A. A., Samvelovna P. K. Peculiarities of the Influence of Metabolic Syndrome on the Course of Coronary Heart Disease //American Journal of Pediatric Medicine and Health Sciences (2993-2149). – 2023. – Т. 1. – №. 8. – С. 396-400.
12. Dilshodovna , A. M., Odylovna , K. F., & Samveilovna , P. K. (2022). Peculiarities of Psychological Disorders in Patients with Acute Coronary Syndrome. INTERNATIONAL JOURNAL OF HEALTH SYSTEMS AND MEDICAL SCIENCES , 1 (6), 203–207. Retrieved from http://inter-publishing.com/index.php/IJHSMS/article/view/695
13. Kristina Samvelovna Pulatova , Timur Mukhitdinovich Pulatov , Mukhammad Olimovich Esankulov THE SPECIFIC FEATURES OF ARTERIAL HYPERTENSION IN OWERWEIGHT PATIENTS WITH PSORIASIS // Academic research in educational sciences. 2021. No. 2. URL: https://cyberleninka.ru/article/n/the-specific-features-of-arterial-hypertension-in-owerweight-patients-with-psoriasis (access date: 05/13/2023).
14. Nasyrova Zarina Akbarovna , Abdulloeva Maftuna Dilshodovna , Usarov Shohruh Abduvahob Ugli STRATIFICATION OF RISK FACTORS IN CORONARY HEART DISEASE // JCRR. 2021. No. 3. URL: https://cyberleninka.ru/article/n/stratifikatsiya-faktorov-riska-pri-ishemicheskoy-bolezni-serdtsa (date of access: 05/13/2023).
15. Pulatova K. Analysis of Ecg and Echo Results in Hypertensive Patients Depending on Bmi Degrees //International Journal of Health Systems and Medical Sciences2023.https://cajmns.centralasianstudies.org/index.php/CAJMNS/article/view/1193